TATA HEALTH (01255) receives additional resumption guidance from the Hong Kong Stock Exchange.

TATA HEALTH (01255) announced that on September 12, 2025, the company received a letter from the Stock Exchange listing additional guidance for the resumption of trading. The letter specified that the company must conduct an independent internal control review and demonstrate that it has established sufficient internal controls and procedures to meet its responsibilities under the listing rules.